Terumo Corporation has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, a specialist in predictive analytics and clinical decision support for healthcare organisations.
“The acquisition of Health Outcomes Sciences and the ePRISM platform expands Terumo’s presence in the digital healthcare arena and represents a compelling growth opportunity for our company. It further allows Terumo to deliver innovative digital solutions, providing healthcare systems with critical data needed to lower the cost of healthcare delivery while substantially improving patient outcomes,” said Toshi Osada, president of Terumo Corporation’s Cardiac and Vascular Company.
ePRISM delivers a patient’s unique risks to physicians prior to treatment, based upon a calculation that includes their unique disease severity, co-morbidities and demographics. The use of validated predictive models in routine care has the capacity to improve the consistency, outcomes and cost-effectiveness of care across various cardiac procedures and care pathways, Terumo said in a press release.
“When combined with Terumo’s 100-year history and commitment to transforming global healthcare, our ePRISM technology will enable healthcare providers to deliver uniquely focused patient care; improving patient satisfaction, decreasing variability, optimising outcomes and minimising costs. This acquisition provides Terumo with a digital solutions platform that can be scaled globally across multiple healthcare segments,” said John Spertus, founder of Health Outcomes Sciences.
The acquisition is expected to close in February 2021. Following the close, the ePRISM platform will be integrated into Terumo Business Edge, a business unit of Terumo Medical Corporation.